1. Search Result
Search Result
Results for "

CYP19

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

1

Fluorescent Dye

4

Natural
Products

2

Isotope-Labeled Compounds

2

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0507
    Sulfathiazole
    5 Publications Verification

    Environmental Pollutants Antibiotic Bacterial Endocrinology Cancer
    Sulfathiazole is an orally active, endocrine disruptor targeting the steroidogenic pathway, specifically enhancing the activity of CYP19 in human adrenal cancer cells (H295R) and upregulating the mRN expression of CYP17, CYP19, and 3β-HSD. Sulfathiazole increases the production of 17-estradiol (E2) and has endocrine disrupting effects on aquatic organisms such as the Japanese medaka fish .
    Sulfathiazole
  • HY-133668

    Drug Metabolite Cytochrome P450 PPAR Endocrinology Cancer
    Monoethyl phthalate is an orally active PDX-1 activator and the major hydrolytic metabolite of Diethyl phthalate (HY-Y0284) in vivo, with reproductive toxicity. Monoethyl phthalate targets aromatase (aromatase/CYP19A1) and PPAR to induce cell proliferation. The plasma protein binding rate of Monoethyl phthalate in rats and humans is lower than that of Diethyl phthalate. It exhibits significant enterohepatic circulation in rats and mainly accumulates in liver tissues. Monoethyl phthalate shows no estrogenic activity in estrogen-dependent human breast cancer cells. Monoethyl phthalate can be used in studies of reproductive toxicity and related environmental endocrine disruption mechanisms .
    Monoethyl phthalate
  • HY-B0507A
    Sulfathiazole sodium
    5 Publications Verification

    Antibiotic Bacterial Endocrinology Cancer
    Sulfathiazole sodium is an orally active, endocrine disruptor targeting the steroidogenic pathway, specifically enhancing the activity of CYP19 in human adrenal cancer cells (H295R) and upregulating the mRN expression of CYP17, CYP19, and 3β-HSD. Sulfathiazole sodium increases the production of 17-estradiol (E2) and has endocrine disrupting effects on aquatic organisms such as the Japanese medaka fish. Sulfathiazole sodium is also a cathodic corrosion inhibitor. It inhibits the corrosion of copper by chloride ions through chemical and physical adsorption on the copper surface, reduces the corrosion current density and shifts the corrosion potential negatively .
    Sulfathiazole sodium
  • HY-116862

    DBF

    Cytochrome P450 Fluorescent Dye Others
    Dibenzylfluorescein (DBF) is a fluorogenic probe (Fluoresecent dye) that acts as a substrate for specific cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2C8, CYP2C9, CYP2C19, and aromatase (CYP19). Dibenzylfluorescein is typically used near its Km value of 0.87-1.9 μM (Ex=485 nm,Em=535 nm). Dibenzylfluorescein is used to detect changes in CYP catalytic activity caused by drugs or disease .
    Dibenzylfluorescein
  • HY-W087008

    Cytochrome P450 Endocrinology Cancer
    7-Hydroxyflavanone is a potent inhibitor of aromatase (CYP19) activity with the IC50 of 65 μM. 7-Hydroxyflavanone exerts various biological effects, including anticarcinogenic, antioxidant and (anti-)estrogenic effects, and modula
    7-Hydroxyflavanone
  • HY-B0507S

    Isotope-Labeled Compounds Antibiotic Bacterial Endocrinology Cancer
    Sulfathiazole-d4 is a deuterium labeled Sulfathiazole. Sulfathiazole is an orally active, endocrine disruptor targeting the steroidogenic pathway, specifically enhancing the activity of CYP19 in human adrenal cancer cells (H295R) and upregulating the mRN expression of CYP17, CYP19, and 3β-HSD. Sulfathiazole increases the production of 17-estradiol (E2) and has endocrine disrupting effects on aquatic organisms such as the Japanese medaka fish .
    Sulfathiazole-d4
  • HY-B0507B

    Antibiotic Bacterial Endocrinology Cancer
    Sulfathiazole (100 μg/mL in acetonitrile) is an orally active, endocrine disruptor targeting the steroidogenic pathway, specifically enhancing the activity of CYP19 in human adrenal cancer cells (H295R) and upregulating the mRN expression of CYP17, CYP19, and 3β-HSD. Sulfathiazole (100 μg/mL in acetonitrile) increases the production of 17-estradiol (E2) and has endocrine disrupting effects on aquatic organisms such as the Japanese medaka fish. Sulfathiazole (100 μg/mL in acetonitrile) is also a cathodic corrosion inhibitor. Sulfathiazole (100 μg/mL in acetonitrile) inhibits the corrosion of copper by chloride ions through chemical and physical adsorption on the copper surface, reduces the corrosion current density and shifts the corrosion potential negatively .
    Sulfathiazole (100 µg/mL in acetonitrile)
  • HY-150775

    Cytochrome P450 Cancer
    CYP19A1-IN-2 (Compound 13h) is a nonsteroidal aromatase (CYP19A1) inhibitor (IC50=0.09 nM). CYP19A1-IN-2 has potential for breast cancer research . CYP19A1-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    CYP19A1-IN-2
  • HY-N9551

    Cytochrome P450 Parasite COX Lipoxygenase Infection Neurological Disease Cancer
    Eriodictyol chalcone is an antioxidant that inhibits multiple key enzymes including 5-LOX (IC50=0.043 μM), aromatase/CYP19A1 (IC50=2.8 μM), PTPase 1B (IC50=1.26 μM), and COX (IC50=34 μM). Eriodictyol chalcone exhibits excellent free radical scavenging activity. Eriodictyol chalcone not only inhibits the growth of plasmodia and enhances the efficacy of Artemisinin (HY-B0094), but also reduces depression-like behaviors in animal models. Eriodictyol chalcone serves as a biosynthetic precursor for Aureusidin (HY-N9834). Eriodictyol chalcone is a potential dietary supplement and herbicide, and it can be applied to research on malaria, depression, breast cancer and other related diseases .
    Eriodictyol chalcone
  • HY-146688

    Cytochrome P450 Cancer
    SYN20028567 is an aromatase (CYP19) inhibitor with an IC50 of 9.4 nM. SYN20028567 can be used for breast cancer research .
    SYN20028567
  • HY-B0507R

    Reference Standards Antibiotic Bacterial Endocrinology Cancer
    Sulfathiazole (Standard) is the analytical standard of Sulfathiazole (HY-B0507). This product is intended for research and analytical applications. Sulfathiazole is an orally active, endocrine disruptor targeting the steroidogenic pathway, specifically enhancing the activity of CYP19 in human adrenal cancer cells (H295R) and upregulating the mRN expression of CYP17, CYP19, and 3β-HSD. Sulfathiazole increases the production of 17-estradiol (E2) and has endocrine disrupting effects on aquatic organisms such as the Japanese medaka fish .
    Sulfathiazole (Standard)
  • HY-RS03440

    Small Interfering RNA (siRNA) Others

    CYP19A1 Rat Pre-designed siRNA Set A contains three designed siRNAs for CYP19A1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CYP19A1 Rat Pre-designed siRNA Set A
    CYP19A1 Rat Pre-designed siRNA Set A
  • HY-RS03439

    Small Interfering RNA (siRNA) Others

    Cyp19a1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cyp19a1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cyp19a1 Mouse Pre-designed siRNA Set A
    Cyp19a1 Mouse Pre-designed siRNA Set A
  • HY-RS03438

    Small Interfering RNA (siRNA) Others

    CYP19A1 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP19A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CYP19A1 Human Pre-designed siRNA Set A
    CYP19A1 Human Pre-designed siRNA Set A
  • HY-B0507AR

    Reference Standards Antibiotic Bacterial Endocrinology Cancer
    Sulfathiazole sodium (Standard) is the analytical standard of Berberine sodium (HY-B0507A). This product is intended for research and analytical applications. Sulfathiazole sodium is an orally active, endocrine disruptor targeting the steroidogenic pathway, specifically enhancing the activity of CYP19 in human adrenal cancer cells (H295R) and upregulating the mRN expression of CYP17, CYP19, and 3β-HSD. Sulfathiazole sodium increases the production of 17-estradiol (E2) and has endocrine disrupting effects on aquatic organisms such as the Japanese medaka fish. Sulfathiazole sodium is also a cathodic corrosion inhibitor. Sulfathiazole sodium inhibits the corrosion of copper by chloride ions through chemical and physical adsorption on the copper surface, reduces the corrosion current density and shifts the corrosion potential negatively .
    Sulfathiazole sodium (Standard)
  • HY-W752436

    Cytochrome P450 Cancer
    (±) Homoeriodictyol is a Aromatase/CYP19 inhibitor that can be used in breast cancer research .
    (±)Homoeriodictyol
  • HY-173279

    Cytochrome P450 Endocrinology
    CYP19A1-IN-1 (Compound 9) is a CYP19A1 inhibitor with an IC50 of 271 nM. CYP19A1-IN-1 inhibits the activity of converting androgens to estrogens by binding to CYP19A1. CYP19A1-IN-1 can be used in the research of sex hormone-related diseases such as estrogen-dependent breast cancer .
    CYP19A1-IN-1
  • HY-155493

    Cytochrome P450 Cancer
    CYP19A1/CYP11B2-IN-1 (Compound X21) is a potent and selective aromatase and aldosterone synthase dual inhibitor with IC50s of 2.3 nM and 29 nM for aromatase (CYP19A1) and aldosterone synthase (CYP11B2), respectively. CYP19A1/CYP11B2-IN-1 has excellent antiproliferative and pro-apoptotic activity against the cancer cell. CYP19A1/CYP11B2-IN-1 can be used for research of breast cancer .
    CYP19A1/CYP11B2-IN-1
  • HY-N17307

    Cytochrome P450 Cancer
    2-Methoxy-5-acetoxyfuranogermacr-1 (10)-en-6-one (compound 20) is an aromatase (CYP19) inhibitor with an IC50 of 0.21 μM against human targets. 2-Methoxy-5-acetoxyfuranogermacr-1 (10)-en-6-one is applicable to research related to breast cancer .
    2-Methoxy-5-acetoxyfuranogermacr-1(10)-en-6-one
  • HY-Z4488

    Drug Intermediate Cancer
    5-Dibromomethyl anastrozole is a synthetic intermediate in the synthesis of the aromatase/CYP19A1 inhibitor Anastrozole (HY-14274).
    5-Dibromomethyl anastrozole
  • HY-133668S

    Isotope-Labeled Compounds Drug Metabolite Cytochrome P450 PPAR Cancer
    Monoethyl phthalate-d4 is the deuterium labeled Monoethyl phthalate. Monoethyl phthalate is an orally active PDX-1 activator and the major hydrolytic metabolite of Diethyl phthalate (HY-Y0284) in vivo, with reproductive toxicity. Monoethyl phthalate targets aromatase (aromatase/CYP19A1) and PPAR to induce cell proliferation. The plasma protein binding rate of Monoethyl phthalate in rats and humans is lower than that of Diethyl phthalate. It exhibits significant enterohepatic circulation in rats and mainly accumulates in liver tissues. Monoethyl phthalate shows no estrogenic activity in estrogen-dependent human breast cancer cells. Monoethyl phthalate can be used in studies of reproductive toxicity and related environmental endocrine disruption mechanisms .
    Monoethyl phthalate-d4
  • HY-182498

    Cytochrome P450 Estrogen Receptor/ERR Cancer
    (Z)-Norendoxifen is an aromatase inhibitor and estrogen receptor modulator. The IC50 value of (Z)-Norendoxifen against aromatase is 102 nM. The EC50 values of (Z)-Norendoxifen for ER-α and ER-β are 27.0 nM and 35.2 nM, respectively. (Z)-Norendoxifen can be used in breast cancer research .
    (Z)-Norendoxifen

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: